Evotec SE (EVOTF)
| Previous close | 10.18 |
| Open | 9.85 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 9.85 - 9.85 |
| 52-week range | 9.85 - 25.48 |
| Volume | |
| Avg. volume | 15 |
| Market cap | 1.745B |
| Beta (5Y monthly) | 1.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.55 |
| Earnings date | 14 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireCENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical researchCompanies amend existing drug discovery partnership for Evotec to lead continued development. Upon Evotec exercising its option, CENTOGENE to receive an option exercise fee and other potential milestone payments and royalties CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 14, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-dr
Insider MonkeyEvotec SE (NASDAQ:EVO) Q4 2023 Earnings Call Transcript
Evotec SE (NASDAQ:EVO) Q4 2023 Earnings Call Transcript April 24, 2024 Evotec SE misses on earnings expectations. Reported EPS is $-0.05 EPS, expectations were $-0.03333. Evotec SE isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, welcome to […]
Simply Wall St.Evotec SE (ETR:EVT) Yearly Results: Here's What Analysts Are Forecasting For This Year
One of the biggest stories of last week was how Evotec SE ( ETR:EVT ) shares plunged 32% in the week since its latest...
